You are viewing: North America Oral Proteins & Peptides Market analysis

The North America Oral Proteins & Peptides Market was valued at $1999.1 Million in 2025 and projected to reach to $5880.7 Million by 2030, representing a compound annual growth rate of 24.1%. North America's oral proteins and peptides market is poised for exceptional growth, expanding from $1,999.1 million in 2025 to $5,880.7 million by 2030.

North America Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

North America Oral Proteins & Peptides Market Trends and Insights

  • This represents a compound annual growth rate of 24.1%, significantly outpacing global trends.
  • North America's advanced healthcare infrastructure, high pharmaceutical R&D investment, and strong regulatory frameworks position the region as a critical hub for oral protein and peptide therapeutics development and commercialization. The North America market is driven by increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery systems, and substantial biotech innovation.
  • North America's pharmaceutical companies are investing heavily in oral formulation technologies to overcome bioavailability challenges inherent to protein and peptide drugs.
  • By 2030, North America is expected to capture a substantial share of global oral protein and peptide revenues, reflecting the region's leadership in precision medicine and therapeutic innovation..

Key Market Statistics

  • CAGR (2025-2030) 24.1% CAGR
  • Market Size, 2025 ~USD 1999.1 Million
  • Forecast, 2030 ~USD 5880.7 Million
  • Geography North America

North America Oral Proteins & Peptides Market Overview

Market Leadership Position :

North America commands the largest share of the global oral proteins and peptides market, with a 2025 valuation of $1,999.1 million, driven by advanced pharmaceutical infrastructure and substantial biotech investments across the US and Canada.

Accelerated Growth Trajectory :

The region's 24.1% CAGR significantly exceeds the global average of 22.1%, reflecting strong demand for innovative oral delivery solutions and increased adoption of peptide-based therapeutics in North American healthcare systems.

Robust Regulatory Environment :

FDA approval pathways and Health Canada's regulatory frameworks provide streamlined market entry for oral protein and peptide formulations, accelerating commercialization and fostering competitive innovation in the North American market.

R&D Investment Concentration :

North America hosts the highest concentration of pharmaceutical R&D spending globally, with major biotech hubs in California, Massachusetts, and Toronto driving breakthrough developments in oral peptide technologies and formulation science.

North America Oral Proteins & Peptides Market Dynamics

  • This trajectory reflects increasing prevalence of chronic diseases, growing patient preference for non-invasive oral therapies, and substantial investments in peptide drug development by leading pharmaceutical companies.
  • The region's sophisticated healthcare infrastructure and reimbursement mechanisms support rapid adoption of novel oral formulations. Key drivers include advancing bioavailability enhancement technologies, expanding pipeline of oral peptide therapeutics, and rising healthcare expenditure across North America.
  • Strategic partnerships between biotech firms and established pharmaceuticals, coupled with FDA's supportive regulatory stance toward innovative delivery systems, will continue accelerating market penetration.
  • By 2030, oral proteins and peptides are expected to represent a significant therapeutic category within North American pharmaceutical markets..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • North America's oral proteins & peptides market will grow from $1,999.1M (2025) to $5,880.7M (2030) at a 24.1% CAGR.
    • North America leads global innovation in oral protein delivery technologies and bioavailability enhancement solutions.
    • North America's robust healthcare infrastructure and regulatory environment accelerate clinical development and market adoption.
    • North America's pharmaceutical and biotech sectors are investing heavily in oral peptide therapeutics for chronic disease management.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    North America Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    Target Audience

    • Pharmaceutical Companies : Pharmaceutical manufacturers require North America market data to prioritize R&D investments, identify acquisition targets, and develop regional commercialization strategies for oral protein and peptide product portfolios.
    • Biotech & Specialty Pharma Firms : Biotech companies need detailed North American market insights to secure venture funding, plan clinical trial strategies, and position oral peptide candidates for FDA approval and market launch in the region's high-value market.
    • Healthcare Investors & PE Firms : Investment professionals require North America market forecasts and growth metrics to evaluate biotech investment opportunities, assess portfolio company valuations, and identify emerging peptide therapeutics companies with strong regional potential.
    • Medical Device & Delivery Technology Providers : Companies developing oral delivery systems and formulation technologies need North American market data to demonstrate addressable market size, validate business cases, and attract partnerships with pharmaceutical manufacturers.
    • Healthcare Policy & Regulatory Bodies : Regulatory agencies and healthcare policymakers require market intelligence on oral proteins and peptides to inform reimbursement policies, establish pricing frameworks, and guide healthcare resource allocation across North America.

    Key Companies in the North America Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    North America vs. other regions

    HowNorth America compares to the other 3 regional blocs covered in this market.

    Europe
    ~USD 3180.3 Million · 21% wtd CAGR ·
    Asia Pacific
    ~USD 1135 Million · 17.2% wtd CAGR ·
    Latin America
    ~USD 650.7 Million · 13.9% wtd CAGR ·

    Countries within North America - compare and drill down

    Country2025 size (native)
    USUSD 5831 Million
    CanadaUSD 116.8 Million

    Country market size visualization

    US
    USD 5831 Million
    Canada
    USD 116.8 Million

    Reasons to Buy this Report

    • Regional Market Dominance Insights : Gain comprehensive understanding of North America's 24.1% CAGR and market leadership position, enabling strategic positioning ahead of competitors in the fastest-growing developed market for oral proteins and peptides.
    • Country-Level Granularity : Access detailed market segmentation for US ($5,831M) and Canada ($116.8M), allowing precise identification of high-opportunity markets and tailored go-to-market strategies for each North American territory.
    • Regulatory & Infrastructure Analysis : Understand FDA approval pathways, Health Canada regulations, and North America's advanced pharmaceutical infrastructure to accelerate product development timelines and optimize market entry strategies for oral peptide formulations.
    • Investment & R&D Opportunity Mapping : Identify biotech hubs, funding trends, and partnership opportunities across North America's concentrated R&D ecosystem, supporting informed investment decisions and strategic alliance development in the peptide therapeutics space.
    • Competitive Landscape & Forecasting : Leverage 2025-2030 projections ($5,880.7M by 2030) to benchmark competitive positioning, anticipate market consolidation, and develop long-term commercial strategies aligned with North America's accelerating peptide market expansion.

    Frequently asked questions

    What is the current market size of oral proteins and peptides in North America?

    North America's oral proteins and peptides market was valued at $1,999.1 million in 2025 and is projected to reach $5,880.7 million by 2030.

    What is the expected growth rate for North America's oral proteins and peptides market?

    North America's oral proteins and peptides market is expected to grow at a compound annual growth rate (CAGR) of 24.1% from 2025 to 2030.

    What factors are driving growth in North America's oral proteins and peptides market?

    Key drivers include increasing chronic disease prevalence, demand for non-invasive drug delivery, substantial biotech R&D investment, and advanced formulation technologies in North America.

    How does North America's oral proteins and peptides market compare to global trends?

    North America's 24.1% CAGR significantly exceeds the global CAGR of 22.1%, reflecting the region's leadership in pharmaceutical innovation and healthcare infrastructure.

    What role does North America play in global oral protein and peptide development?

    North America is a critical hub for oral protein and peptide therapeutics development, with leading pharmaceutical and biotech companies pioneering delivery technologies and clinical applications.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status